https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22523 Wed 11 Apr 2018 13:47:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:3636 Wed 11 Apr 2018 12:18:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33182 Thu 13 Jan 2022 10:31:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10455 Sat 24 Mar 2018 08:09:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10465 Sat 24 Mar 2018 08:09:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20099 18 months) from auto-HCT to URD allo-HCT was associated with significantly lower riak of relapse (HR, 0.19; 95% CI, 0.09-0.38; P <.001) and improved leukemia-free survival (HR, 0.53; 95% CI, 0.34-0.84; P = .006). URD allo-HCT after auto-HCT relapse resulted in 20% long-term leukemia-free survival, with the best results seen in patients with a longer interval to secondary URD transplantation, with a Karnofsky Performance Status score ≥90%, in complete remission, and using an RIC regimen. Further efforts to reduce treatment-related mortaility and relapse are still needed.]]> Sat 24 Mar 2018 08:00:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45459 Fri 28 Oct 2022 14:22:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42242 90% of patients exhibiting concentrations within the defined target range throughout the entire treatment course. Additional work to formally establish target therapeutic concentrations is required; however, this study provides a valuable first step in determining optimal ribavirin treatment regimens for paramyxovirus infections in the lung transplant population.]]> Fri 19 Aug 2022 11:56:24 AEST ]]>